CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress
Abstract
CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast cancer cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2020
- Source ID
- 10.1186/s13058-020-01361-z
Entities
People
- Benjamin T Spike
- Berhane M. Hagos
- Brooke L. Gates
- David W. Freeman
- Elnaz Mirzaei Mehrabad
- Evan Booker
- Hyrum T. Diesen
- Kishan Bhakta
- Masami Kachi
- Mathias Leblanc
- Ozlen Balcioglu
- Peter C. Gray
- Richard E. Heinz
- Supraja Ranganathan
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- Susan G. Komen for the Cure